Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Purchased by US Bancorp DE

US Bancorp DE boosted its holdings in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 6.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,089 shares of the biopharmaceutical company’s stock after acquiring an additional 2,730 shares during the period. US Bancorp DE’s holdings in Horizon Therapeutics Public were worth $2,790,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. CoreCap Advisors LLC acquired a new position in shares of Horizon Therapeutics Public during the 2nd quarter worth approximately $33,000. Allworth Financial LP lifted its position in shares of Horizon Therapeutics Public by 936.7% in the third quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 562 shares in the last quarter. Steward Financial Group LLC acquired a new stake in shares of Horizon Therapeutics Public during the second quarter valued at $41,000. Samalin Investment Counsel LLC purchased a new stake in Horizon Therapeutics Public during the 1st quarter worth about $41,000. Finally, Stonebridge Capital Advisors LLC raised its stake in Horizon Therapeutics Public by 550.0% in the 1st quarter. Stonebridge Capital Advisors LLC now owns 650 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 550 shares during the last quarter. Hedge funds and other institutional investors own 91.01% of the company’s stock.

Horizon Therapeutics Public Trading Up 0.0 %

NASDAQ HZNP opened at $113.24 on Friday. The firm has a market capitalization of $25.66 billion, a price-to-earnings ratio of 46.41, a PEG ratio of 1.74 and a beta of 1.16. The company has a debt-to-equity ratio of 0.51, a quick ratio of 3.74 and a current ratio of 3.96. Horizon Therapeutics Public Limited has a one year low of $57.84 and a one year high of $117.49. The company’s 50 day moving average price is $98.48 and its 200 day moving average price is $79.24.

Horizon Therapeutics Public (NASDAQ:HZNPGet Rating) last issued its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported $1.25 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.25. The business had revenue of $925.36 million for the quarter, compared to the consensus estimate of $888.93 million. Horizon Therapeutics Public had a net margin of 15.51% and a return on equity of 24.59%. On average, sell-side analysts predict that Horizon Therapeutics Public Limited will post 4.23 EPS for the current year.

Insider Buying and Selling at Horizon Therapeutics Public

In other news, EVP Jeffrey W. Sherman sold 5,187 shares of the company’s stock in a transaction dated Friday, January 6th. The stock was sold at an average price of $113.29, for a total value of $587,635.23. Following the completion of the sale, the executive vice president now owns 49,314 shares of the company’s stock, valued at $5,586,783.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, EVP Jeffrey W. Sherman sold 5,187 shares of the business’s stock in a transaction on Friday, January 6th. The shares were sold at an average price of $113.29, for a total transaction of $587,635.23. Following the transaction, the executive vice president now directly owns 49,314 shares of the company’s stock, valued at $5,586,783.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Jeffrey W. Sherman sold 28,352 shares of the firm’s stock in a transaction on Monday, December 12th. The shares were sold at an average price of $111.45, for a total transaction of $3,159,830.40. Following the sale, the executive vice president now directly owns 54,501 shares of the company’s stock, valued at $6,074,136.45. The disclosure for this sale can be found here. Insiders have sold 36,907 shares of company stock valued at $4,128,218 over the last three months. 2.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HZNP shares. Stifel Nicolaus cut shares of Horizon Therapeutics Public from a “buy” rating to a “hold” rating and decreased their price target for the stock from $138.00 to $116.50 in a research note on Monday, December 12th. Guggenheim downgraded Horizon Therapeutics Public from a “buy” rating to a “neutral” rating and boosted their price target for the company from $98.00 to $116.50 in a report on Tuesday, December 13th. Wells Fargo & Company cut Horizon Therapeutics Public from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $118.00 to $116.50 in a report on Monday, December 12th. StockNews.com raised Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. Finally, HC Wainwright began coverage on Horizon Therapeutics Public in a research report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 target price on the stock. Eight analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $111.42.

About Horizon Therapeutics Public

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Further Reading

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.